高级检索
当前位置: 首页 > 详情页

Early PROs after Thoracoscopic Segmentectomy versus Wedge Resection for Small-sized Peripheral NSCLC

| 认领 | 导出 |

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Sichuan Canc Hosp & Inst, Chengdu, Peoples R China
出处:
ISSN:

关键词: Patient-reported outcomes Non-small cell lung cancer surgical operation

语种:
WOS:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区:
出版当年[2023]版:
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版:
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者:
第一作者机构: [1]Sichuan Canc Hosp & Inst, Chengdu, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Early Postoperative Patient-Reported Outcomes After Thoracoscopic Segmentectomy Versus Lobectomy for Small-Sized Peripheral Non-small-cell Lung Cancer [2]Comparison of early patient-reported outcomes between uniportal thoracoscopic segmentectomy and wedge resection for peripheral small-sized non-small-cell lung cancer [3]Surgical outcomes and patient-reported outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy [4]ASO Visual Abstract: Early Postoperative Patient-Reported Outcomes After Thoracoscopic Segmentectomy Versus Lobectomy for Small-Sized Peripheral Non-small Cell Lung Cancer. [5]ASO Visual Abstract: Early Postoperative Patient-Reported Outcomes After Thoracoscopic Segmentectomy Versus Lobectomy for Small-Sized Peripheral Non-small Cell Lung Cancer [6]Comparison of early postoperative patient-reported outcomes after multiportal robotic-assisted thoracoscopic surgery and uniportal video-assisted thoracoscopic surgery for non-small cell lung cancer [7]Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer. [8]Early PROs After Uniportal Thoracoscopic Lobectomy vs Da Vinci Robotic-assisted Thoracoscopic Lobectom [9]Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. [10]EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs)

资源点击量:43370 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号